Last updated on 2-2-2023 by Pauline De Wurstemberger
Downloaden 505.84 KBPeer reviewed scientific article
Engels
SCIENSANO
Auteurs
Aline Hébrant; M Lammens; C Van den Broeck; N. D’Haene; J Van den Oord; A. Vanderstichele; A Dendooven; P Neven; K Punie; G Floris; J Van der Meulen; H A Poirel; C Dooms; S Rottey; T Boterberg; L Brochez; MC Burlacu; G Costante; D Creytens; De Paepe, P; R De Pauwn; B Decallonne; F Dedeurwaerdere; H Denys; L Ferdinande; R Forsyth; M Garmyn; T Gevaert; J De Grève; E Govaerts; E Hauben; J Kerger; O Kholmanskikh Van Criekingen; V Kruse; Y Lalami; L Lapeire; P Lefesvre; JP Machiels; B Maes; G Martens; M Remmelink; I Salmon; R Sciot; S Tejpar; K Van de Vijver; L Van de Voorde; I Van den Berghe; A Van den Bruel; K Vandecasteele; L Vanwalleghem; K Vermaelen; R Salgado; E Wauters; B Weynand; Els Van Valckenborgh; Gordana Raicevic; Marc Van den Bulcke; P PauwelsTrefwoorden
Samenvatting:
In order to advise the Federal Government on the reimbursement of molecular tests related to Personalised Medicine in Oncology, the Commission of Personalised Medicine (ComPerMed), represented by Belgian experts, has developed a methodology to classify molecular testing in oncology. The different molecular tests per cancer type are represented in algorithms and are annotated with a test level reflecting their relevance based on current guidelines, drug approvals and clinical data. The molecular tests are documented with recent literature, guidelines and a brief technical description. This m…